Cargando…

Cardiac Drug Safety : a Bench to Bedside Approach.

Ensuring the safety of new medical products remains a major challenge for the pharmaceutical industry. Cardiac safety, particularly drug-induced heart rhythm abnormalities, remains an important cause of pipeline attrition and has resulted in countless major product recalls or label changes. The risk...

Descripción completa

Detalles Bibliográficos
Clasificación:Libro Electrónico
Autor principal: Killeen, Matthew J.
Formato: Electrónico eBook
Idioma:Inglés
Publicado: Singapore : World Scientific, 2012.
Temas:
Acceso en línea:Texto completo

MARC

LEADER 00000cam a2200000Mi 4500
001 EBSCO_ocn794328376
003 OCoLC
005 20231017213018.0
006 m o d
007 cr |n|---|||||
008 120528s2012 si ob 001 0 eng d
040 |a EBLCP  |b eng  |e pn  |c EBLCP  |d OCLCQ  |d LGG  |d YDXCP  |d N$T  |d IDEBK  |d OCLCQ  |d CDX  |d DEBSZ  |d OCLCQ  |d E7B  |d STF  |d OCLCF  |d DEBBG  |d UKDOC  |d OCLCQ  |d OCL  |d OCLCQ  |d D6H  |d LOA  |d OCLCO  |d JBG  |d OCLCO  |d OCLCA  |d AGLDB  |d OCLCO  |d MOR  |d PIFAG  |d ZCU  |d OCLCO  |d OCLCQ  |d MERUC  |d OCLCO  |d OCLCQ  |d OCLCO  |d OCLCA  |d U3W  |d OCLCO  |d WRM  |d VNS  |d OCLCO  |d VTS  |d OCLCO  |d NRAMU  |d ICG  |d OCLCO  |d TOF  |d OCLCO  |d AU@  |d OCLCO  |d OCLCQ  |d OCLCO  |d OTZ  |d OCLCO  |d OCLCA  |d REC  |d DKC  |d OCLCO  |d OCLCQ  |d OCLCO  |d M8D  |d OCLCO  |d UKAHL  |d OCLCQ  |d OCLCO  |d OCLCA  |d UKCRE  |d AJS  |d LUU  |d OCLCO  |d OCLCQ  |d QGK  |d OCLCO 
019 |a 793804672  |a 794902679  |a 797852507  |a 817084766  |a 961685992  |a 966211954  |a 988409859  |a 988476737  |a 992030749  |a 1037737880  |a 1038664895  |a 1045555365  |a 1065914499  |a 1086551858  |a 1153534694  |a 1259218625 
020 |a 9789814317467  |q (electronic bk.) 
020 |a 9814317462  |q (electronic bk.) 
020 |a 1280669225 
020 |a 9781280669224 
020 |z 9789814317450 
020 |z 9814317454 
020 |a 9786613646156 
020 |a 6613646156 
029 1 |a AU@  |b 000052904359 
029 1 |a AU@  |b 000052978384 
029 1 |a AU@  |b 000062341372 
029 1 |a DEBBG  |b BV040834075 
029 1 |a DEBBG  |b BV043030782 
029 1 |a DEBBG  |b BV044165368 
029 1 |a DEBSZ  |b 379327694 
029 1 |a DEBSZ  |b 446513202 
029 1 |a DEBSZ  |b 454900775 
029 1 |a NZ1  |b 14538227 
029 1 |a AU@  |b 000066420194 
029 1 |a AU@  |b 000073145874 
035 |a (OCoLC)794328376  |z (OCoLC)793804672  |z (OCoLC)794902679  |z (OCoLC)797852507  |z (OCoLC)817084766  |z (OCoLC)961685992  |z (OCoLC)966211954  |z (OCoLC)988409859  |z (OCoLC)988476737  |z (OCoLC)992030749  |z (OCoLC)1037737880  |z (OCoLC)1038664895  |z (OCoLC)1045555365  |z (OCoLC)1065914499  |z (OCoLC)1086551858  |z (OCoLC)1153534694  |z (OCoLC)1259218625 
043 |a n-cn--- 
050 4 |a QC903 .S86 2012 
060 0 0 |a 2012 D-923 
060 1 0 |a QV 152 
072 7 |a MED  |x 071000  |2 bisacsh 
072 7 |a TEC  |x 010010  |2 bisacsh 
072 7 |a MMG  |2 bicssc 
082 0 4 |a 363.738/74  |a 363.73874  |a 615.71 
049 |a UAMI 
100 1 |a Killeen, Matthew J. 
245 1 0 |a Cardiac Drug Safety :  |b a Bench to Bedside Approach. 
260 |a Singapore :  |b World Scientific,  |c 2012. 
300 |a 1 online resource (189 pages) 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
505 0 |a Foreword; "Et causae quoque aestimatio saepe morbum solvit"* [Celsus: Prooemium 69, De Medicina]; Preface; Chapter 1 Challenges Facing the Pharmaceutical Industry in the 21st Century; Introduction; The Impact of Cardiac Toxicity on the Pharmaceutical Industry; References; Chapter 2 The Cellular Basis of Cardiac Electrophysiology; Introduction; The Initiation of the Heart Beat; The Ventricular Cardiac Action Potential; The Relationship Between the Cardiac Action Potential and the Electrocardiogram; Ion Channels Underlying the Cardiac Action Potential; Sodium channels. 
505 8 |a Calcium channelsPotassium channels; Cardiac potassium channels; The transient outward potassium channel; Delayed rectifier potassium channels; The ultra rapid delayed rectifier potassium channel; The HERG potassium channel; The slowly activating delayed rectifier potassium channel; Inwardly rectifying potassium channels; Species-dependent variability of potassium channels; Potassium channel subunits; Summary; References; Chapter 3 Clinical Arrhythmia Syndromes; Introduction; The Long QT Syndrome; Congenital Long QT Syndrome; Drug-Induced QT Prolongation; Summary; References. 
505 8 |a Chapter 4 The Mechanisms Underlying Cardiac ArrhythmiasIntroduction; Mechanisms Underlying Cardiac Arrhythmias; Abnormal Automaticity; Early and Delayed Afterdepolarizations; Re-entry; Transmural Dispersion of Repolarization; How does Action Potential and QT Prolongation Generate Arrhythmias?; Does the M-Cell Play a Role in Arrhythmia Induction in Humans?; Using Mouse Models to Study Arrhythmia Mechanisms; Experimental Studies Exploring the Relationship Between Changes in Transmural Repolarization Gradients and Arrhythmias in Mouse Hearts. 
505 8 |a Arrhythmia Mechanisms and Novel Antiarrhythmic Approaches Identified Using the Hypokalemic Mouse ModelSummary; References; Chapter 5 The Mechanisms Underlying Drug-Induced Arrhythmias; Introduction; The Classical Model of Drug-Induced QT Prolongation and Proarrhythmia: HERG Blockade; Additional Mechanisms Contributing to Drug-Induced Arrhythmias; Drug-Induction Activation of Depolarizing Ion Channels; Drug-Induced Changes in Ion Channel Expression; Drug-Induced Sodium Channel Dysfunction; Summary; References; Chapter 6 Assessing Cardiac Safety in Drug Development; Introduction. 
505 8 |a Preclinical Evaluation of Cardiac Drug SafetyThe ICH S7B Guidelines; Single Cell Safety Studies; The Purkinje Fiber Model; The Ventricular Wedge Model; Isolated Heart Models; In Vivo Models; The Impact of Species-Related Differences in Cardiac Electrophysiology on Preclinical Drug Safety Assessment; Methods to Provoke Arrhythmias in Preclinical Studies; Programmed electrical stimulation; Reductions in the extracellular K+ concentration; Clinical Evaluation of Cardiac Safety; The Thorough QT study; Thorough QT study design; Additional Biomarkers to Detect Drug-Induced Proarrhythmia. 
500 |a Variability of repolarization. 
520 |a Ensuring the safety of new medical products remains a major challenge for the pharmaceutical industry. Cardiac safety, particularly drug-induced heart rhythm abnormalities, remains an important cause of pipeline attrition and has resulted in countless major product recalls or label changes. The risk of encountering this major adverse event continues to shape the drug development and regulatory landscape. Extensive research over the past decade has shed light on the root causes of arrhythmias that are triggered by medications and has helped drive, and optimize, drug safety testing. However, curr. 
588 0 |a Print version record. 
504 |a Includes bibliographical references and index. 
546 |a English. 
590 |a eBooks on EBSCOhost  |b EBSCO eBook Subscription Academic Collection - Worldwide 
650 0 |a Arrhythmia  |x Treatment. 
650 0 |a Drugs  |x Safety regulations  |z Canada. 
650 2 |a Drug-Related Side Effects and Adverse Reactions  |x prevention & control 
650 2 |a Heart  |x drug effects 
650 6 |a Arythmie  |x Traitement. 
650 6 |a Médicaments  |x Sécurité  |x Règlements  |z Canada. 
650 7 |a MEDICAL  |x Pharmacology.  |2 bisacsh 
650 7 |a TECHNOLOGY & ENGINEERING  |x Environmental  |x Pollution Control.  |2 bisacsh 
650 7 |a Arrhythmia  |x Treatment  |2 fast 
650 7 |a Drugs  |x Safety regulations  |2 fast 
651 7 |a Canada  |2 fast 
776 0 8 |i Print version:  |a Killeen, Matthew J.  |t Cardiac Drug Safety : A Bench to Bedside Approach.  |d Singapore : World Scientific, ©2012  |z 9789814317450 
856 4 0 |u https://ebsco.uam.elogim.com/login.aspx?direct=true&scope=site&db=nlebk&AN=457178  |z Texto completo 
938 |a 123Library  |b 123L  |n 114800 
938 |a Askews and Holts Library Services  |b ASKH  |n AH25565234 
938 |a Coutts Information Services  |b COUT  |n 23981151 
938 |a EBL - Ebook Library  |b EBLB  |n EBL919080 
938 |a ebrary  |b EBRY  |n ebr10563572 
938 |a EBSCOhost  |b EBSC  |n 457178 
938 |a ProQuest MyiLibrary Digital eBook Collection  |b IDEB  |n 364615 
938 |a YBP Library Services  |b YANK  |n 7280427 
994 |a 92  |b IZTAP